Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Gritstone bio wins $433 million US contract for COVID vaccine study
- By Reuters
- Bengaluru
- Sep 28, 2023
Gritstone bio on Wednesday secured a $433 million contract by the U.S. government to conduct a mid-stage study of its selfamplifying mRNA COVID-19 vaccine candidate.
The contract is a part of "Project NextGen," an initiative by the U.S. Department of Health and Human Services to advance a pipeline of new, innovative vaccines and therapeutics providing broader and more durable protection against COVID-19 infection.
Gritstone's shares rose 36.1 per cent to $1.61 after the bell.
The study will compare the efficacy, safety and immunogenicity of Gritstone's COVID-19 vaccine candidate with an approved vaccine.
Gritstone plans to initiate the mid-stage study in the first quarter of next year.
The contract was awarded by the Biomedical Advanced Research and Development Authority, a U.S. federal agency that funds disease-fighting technology.